36results about "Proteoglycans" patented technology

This new chimeric antigen receptor (CAR) T-cell therapy effectively treats cancer while minimizing the risk of dangerous inflammatory responses such as cytokine release syndrome. [Solution] An isolated nucleic acid sequence encoding a CAR, wherein the CAR includes an antigen-binding domain specific to glypican 3 (GPC3), the antigen-binding domain has an equilibrium dissociation constant (KD) of approximately 100 nanomoles (nM) or less, and the CAR construct provides an isolated nucleic acid sequence that does not induce cytokine production in GPC3-expressing cells.

A mesoangioblast composition is disclosed, in which the mesoangioblasts (MABs) are engineered to express a truncated agrin protein.

A protein polymer and a production process therefor. The protein polymer is obtained by means of stimulating MSCs, lysing same, and separating and purifying same. The protein polymer has a strong capability to repair oxidative damage, and thus can reduce the range of cerebral infarction, improve neural functions, inhibit the level of neuroinflammation, and increase the number of surviving neurons.

The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and / or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and / or treating a hematological cancer in a subject.

Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 (“a GPC-CAR”); and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells.

Provided is an application of a protein polymer in the preparation of a drug for treating autism. Research has found that protein polymers derived from mesenchymal stem cells stimulated under stress conditions, such as ultraviolet irradiation, have a certain therapeutic effect on autism, providing a possibility for the treatment of autism.

The present disclosure provides an agent capable of reducing endotoxin and used for reducing endotoxin in animal tissue-derived proteoglycan, and a method for producing proteoglycan and capable of reducing endotoxin. The agent of the present disclosure for reducing endotoxin in the animal tissue-derived proteoglycan comprises a nonionic surfactant.

The present invention relates to the use of MayDay peptide fragments designated decorin 31-170, decorin 31-188, decorin 31-177, decorin 31-169, or decorin 1-188 (the N-terminal fragment of the decorin protein) in the treatment and prevention of soft tissue inflammation and related disorders such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, osteoarthritis, anal fistula, and lupus. Methods of modulating tissue repair and modulating stem cell mobilization are also contemplated in the present invention.

A protein polymer and a use thereof in the treatment of Alzheimer's disease. The protein polymer is obtained by stimulating MSCs, and then lysing the MSCs and performing separation and purification. The protein polymer has a strong oxidative damage repair ability, can improve Alzheimer's disease-related biomarker abnormalities, and has a significant treatment effect on Alzheimer's disease.

Provided are CAR-T compositions against GPC3, including chimeric receptors, and engineered immune cells against GPC3. The present disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells. The GPC3 CAR compositions provided herein can be used to treat some cancers.

Provided are CAR-T compositions that are directed to GPC3, including chimeric receptors, and engineered immune cells to GPC3. The disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells. GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

The present disclosure provides an agent capable of reducing endotoxin and used for reducing endotoxin in animal tissue-derived proteoglycan, and a method for producing proteoglycan and capable of reducing endotoxin. The agent of the present disclosure for reducing endotoxin in the animal tissue-derived proteoglycan comprises a nonionic surfactant.

The present invention relates to homing peptide-directed decorin conjugates for the treatment of epidermolysis bullosa, and corresponding methods of treatment. The use of novel homing peptides enables the targeting of the conjugates in vivo to specifically home to the skin and skin wounds by systemic administration.

The presently claimed and described technology provides vaccine compositions comprising at least two mutant-calreticulin (CALR)-peptides, wherein the at least two peptides have overlapping sequences and methods for administration of the vaccine compositions to induce or elicit an antitumor response or improve or enhance antitumor T cell immunity and methods of preventing, treating, reducing, or slowing progression or development of a hematological malignancy in a subject with a calreticulin mutation.

Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 ("a GPC-CAR"); and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells.

The present disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells that target glypican 3.

The present disclosure produces proteoglycan in a simpler manner than known methods for producing proteoglycan, and provides a method capable of producing proteoglycan with a core protein and sugar chains bonded. The method for producing proteoglycan of the present disclosure includes: extracting an extract c proteoglycan from a tissue of an animal. The proteoglycan comprises a core protein and a sugar chain, and the core protein and the sugar chain are bonded.

Use of a protein polymer in the treatment of amyotrophic lateral sclerosis. The protein polymer is obtained by stimulating and subsequently lysing mesenchymal stem cells, followed by isolation and purification. In SOD1 mutant mouse experiments, the protein polymer can significantly increase the number of motor neurons in the spinal anterior horn, ameliorate muscle atrophy, improve the motor ability of mice, and prolong the survival time of mice. In clinical trials, the protein polymer exhibits the effect of blocking the progression of amyotrophic lateral sclerosis, can reduce the concentration of TDP-43 protein in cerebrospinal fluid, and can increase the concentration of TDP-43 protein in serum.

Provided herein are compositions, systems, kits, and methods for treating glial scarring caused by injury to a central nervous system (CNS) site by administering a CSPG reduction peptide (CRP), or a nucleic acid sequence encoding the CRP. In particular embodiments, CNS site is the result of a stroke in a subject (e.g., human subject that has had a stroke). In certain embodiments, the CRP is composed of a cell membrane penetrating domain, a lysosome targeting domain, and a chondroitin sulfate proteoglycan (CSPG) binding domain.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and / or retained intra-or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

The present invention relates to the use of MayDay peptide fragments designated decorin 31-170, decorin 31-188, decorin 31-177, decorin 31-169, or decorin 1-188 (the N-terminal fragment of the decorin protein) in the treatment and prevention of respiratory inflammation and related disorders such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and pulmonary fibrosis. Methods for modulating tissue repair and stem cell mobilization are also contemplated in the present invention.

The disclosure provides amino acid sequences (e.g., antibodies) that can bind Glypican 3 Protein (GPC3). The disclosure relates to antigen binding fragments of GPC3 antibodies, conjugates, including immunoconjugates, of GPC3 antibodies, bispecific antibodies that include GPC3 antibodies, and related compositions and formulations. The disclosure also relates to methods for using the sequences, e.g., GPC3 antibodies and antigen-binding fragments thereof, in the treatment of GPC3-related diseases, disorders, and conditions including cell proliferative diseases such as cancer, and more particularly, liver cancer.

A protein polymer and its application in treating Alzheimer's disease. The protein polymer is obtained by stimulating MSCs to split, and is separated and purified. The protein polymer has strong oxidative damage repair capacity, can improve the abnormal condition of Alzheimer's disease related biomarkers, and has obvious therapeutic effect on Alzheimer's disease.

A protein polymer and its application in treating spinocerebellar ataxia. The protein polymer is obtained by stimulating MSCs to split, and is separated and purified. The protein polymer has strong oxidative damage repair capacity, can relieve cell stress state by regulating cell gene expression pathway, and promotes cells to restore normal morphology and function.

Disclosed is a mesoderm vascular mother cell composition in which the mesoderm vascular mother cells (MAB) are engineered to express a truncated aggregation protein.

The present invention relates to a homing peptide-derived decorin conjugate for use in the treatment of epidermolysis bullosa, and a corresponding method of treatment. The use of a novel homing peptide enables the conjugate to target-specifically home to skin and skin wounds in vivo upon systemic administration.

The present invention relates to the use of MayDay peptide fragments designated decorin 31-170, decorin 31-188, decorin 31-177, decorin 31-169, or decorin 1-188 (an N-terminal fragment of the decorin protein) in the treatment or prevention of tissue ischemia and diseases associated with tissue ischemia, such as myocardial infarction (MI), reperfusion ischemia, organ transplantation, wound healing, stroke, cardiomyopathy, and heart failure in a subject. Methods of modulating tissue repair and modulating stem cell mobilization are also contemplated in the present invention.

The invention is based in part on the identification of PTK7 as a signalling receptor for C-terminal (domains III-IV) CCN2, and in part on the finding that GPC-1 and GPC-4 may act (individually or in combination) as coreceptors for CCN ligands. The invention relates to the therapeutic use of agents that bind to PTK7 and have PTK7 antagonist activity, agents that inhibit expression of PTK7, agents comprising a PTK polypeptide or a fragment thereof, agents that bind to a GPC coreceptor for CCN ligand and thus inhibit formation of GPC-CCN ligand-PTK7 complexes, agents that inhibit expression of GPCs. or agents comprising a GPC polypeptide or fragment thereof. The invention also relates to pharmaceutical compositions comprising such agents, and screening methods for their identification.